SlideShare a Scribd company logo
Discover. Educate. Care. Lead.
Genomic Analysis of Unique Uveal
Melanoma (UM) Cases
Huntersville Project
22 reported cases of uveal melanoma in Huntersville, NC
(15 females, 7 males)
Consented 11 patients/family members for archival tissue collection
Obtained 7 primary (6 enucleation, 1 FNA) and 2 metastatic (liver)
tumor samples
*Tissue missing or inadequate in other cases
Whole genome sequencing (40X-80X) on 6 enucleation and 2 liver
samples underway – anticipate results in May-June 2019
DNA Structure
National Human Genome Research Institute
DNA Structure | BioNinja
Whole Genome Sequencing (WGS)
Figure out the cancer’s entire DNA sequence (all 6.4 billion letters)
 Step 1: Separate tumor and adjacent normal tissue
 Step 2: Extract DNA from tumor and matched normal tissue
 Step 3: Whole genome sequencing (New York Genome Center)
National Human Genome Research Institute
corneaoptic nerve
tumor
What can we learn from WGS?
Whole
genome
sequencing
Compare to public
genome databases e.g.
The Cancer Genome
Atlas
Compare to genomic data
from other unique UM
populations e.g. Auburn, AL
Identify mutational
signatures that may point
to carcinogen exposure or
specific mutational
process
More thorough
evaluation of key driver
mutations such as BAP1
Molecular landscape of uveal melanoma
Field MG et al. Nature Communications 2018.
Royer-Bertrand B et al. Am J Hum Genet 2016.
UV mutational signature
Relationship between UV exposure and UM risk is unclear:
welding identified as significant risk factor, but all forms of
sun exposure were non-significant
Characterized by CT transitions at pyrimidine dimers,
including CCTT
https://courses.lumenlearning.com/microbiology/chapter/mutations/
https://cancer.sanger.ac.uk/cosmic/signatures
UV light triggers formation
of covalent bonds between
adjacent cytosine (C) or
thymine (T) bases leads
to DNA kinking and faulty
replication
Pyrimidine
dimer
Pyrimidine
dimer
Error-prone polymerase misreads template
C to T mutation at site of
adjacent pyrimidines
Tobacco mutational signature
High prevalence of CA transversions on transcribed strand
Polycyclic hydrocarbons and other carcinogens found in
tobacco smoke interact with DNA to form bulky adducts on
guanine (G)
Principles of Cancer Biology, ©2006 Pearson
en.wikipidia.org
Activated
benzo(a)pyrene
30 identified mutational signatures
Signature 22. Aristolochic acid
Signature 24. Aflatoxin B1
Signature 2. Activated APOBEC (possible viral etiology)

More Related Content

What's hot

translational_medecine_56
translational_medecine_56translational_medecine_56
translational_medecine_56
Dago Noel
 
Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...
Gul Muneer
 
Cancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methodsCancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methods
mahdi hatami
 
MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...
MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...
MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...
European School of Oncology
 
Anti-cancer stem cell drug starts clinical trials
Anti-cancer stem cell drug starts clinical trialsAnti-cancer stem cell drug starts clinical trials
Anti-cancer stem cell drug starts clinical trials
randazzov
 
Jessian eneida
Jessian eneidaJessian eneida
Jessian eneida
carolinamontanez
 
Puja das 2
Puja das 2Puja das 2
Puja das 2
pujaldas
 
SSGMO
SSGMOSSGMO
poster_Xingzhi2
poster_Xingzhi2poster_Xingzhi2
poster_Xingzhi2
Xingzhi Chen
 
Plegable ppp
Plegable pppPlegable ppp
Plegable ppp
alejandralvarez
 
neha_ppt
neha_pptneha_ppt
neha_ppt
Neha Gupta
 
A Novel Therapeutic Strategy to Address Cancer
A Novel Therapeutic Strategy to Address CancerA Novel Therapeutic Strategy to Address Cancer
A Novel Therapeutic Strategy to Address Cancer
Aethlon Medical, Inc.
 
Exosomes Biogenesis&Therapeutics
Exosomes Biogenesis&TherapeuticsExosomes Biogenesis&Therapeutics
Exosomes Biogenesis&Therapeutics
CandySwift_NY
 
Folding
FoldingFolding
Published-PageOne
Published-PageOnePublished-PageOne
Published-PageOne
Scott Tarone
 

What's hot (15)

translational_medecine_56
translational_medecine_56translational_medecine_56
translational_medecine_56
 
Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...
 
Cancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methodsCancer stem cells &new therapeutics methods
Cancer stem cells &new therapeutics methods
 
MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...
MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...
MCO 2011 - Slide 18 - M.R. Alison - Joint medics and nurses spotlight session...
 
Anti-cancer stem cell drug starts clinical trials
Anti-cancer stem cell drug starts clinical trialsAnti-cancer stem cell drug starts clinical trials
Anti-cancer stem cell drug starts clinical trials
 
Jessian eneida
Jessian eneidaJessian eneida
Jessian eneida
 
Puja das 2
Puja das 2Puja das 2
Puja das 2
 
SSGMO
SSGMOSSGMO
SSGMO
 
poster_Xingzhi2
poster_Xingzhi2poster_Xingzhi2
poster_Xingzhi2
 
Plegable ppp
Plegable pppPlegable ppp
Plegable ppp
 
neha_ppt
neha_pptneha_ppt
neha_ppt
 
A Novel Therapeutic Strategy to Address Cancer
A Novel Therapeutic Strategy to Address CancerA Novel Therapeutic Strategy to Address Cancer
A Novel Therapeutic Strategy to Address Cancer
 
Exosomes Biogenesis&Therapeutics
Exosomes Biogenesis&TherapeuticsExosomes Biogenesis&Therapeutics
Exosomes Biogenesis&Therapeutics
 
Folding
FoldingFolding
Folding
 
Published-PageOne
Published-PageOnePublished-PageOne
Published-PageOne
 

Similar to Unique Populations - 2019 CURE OM Symposium

The Cancer Genome Atlas Update
The Cancer Genome Atlas UpdateThe Cancer Genome Atlas Update
The Cancer Genome Atlas Update
Melanoma Research Foundation
 
ACC Cancer Cell May 2016
ACC Cancer Cell May 2016ACC Cancer Cell May 2016
ACC Cancer Cell May 2016
Thomas Giordano, MD, PhD
 
Alain Toledano : Test and genomic profile : what future in breast cancer trea...
Alain Toledano : Test and genomic profile : what future in breast cancer trea...Alain Toledano : Test and genomic profile : what future in breast cancer trea...
Alain Toledano : Test and genomic profile : what future in breast cancer trea...
breastcancerupdatecongress
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
AnonIshanvi
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
daranisaha
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
JohnJulie1
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
NainaAnon
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
semualkaira
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
semualkaira
 
Critical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdfCritical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdf
semualkaira
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
EditorSara
 
CRC CHP final PDF
CRC CHP final PDFCRC CHP final PDF
CRC CHP final PDF
ashrafdallol
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
daranisaha
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
semualkaira
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
semualkaira
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
ClinicsofOncology
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
semualkaira
 
Cadher
CadherCadher
Cadher
ibtesam99
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
AnonIshanvi
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
JohnJulie1
 

Similar to Unique Populations - 2019 CURE OM Symposium (20)

The Cancer Genome Atlas Update
The Cancer Genome Atlas UpdateThe Cancer Genome Atlas Update
The Cancer Genome Atlas Update
 
ACC Cancer Cell May 2016
ACC Cancer Cell May 2016ACC Cancer Cell May 2016
ACC Cancer Cell May 2016
 
Alain Toledano : Test and genomic profile : what future in breast cancer trea...
Alain Toledano : Test and genomic profile : what future in breast cancer trea...Alain Toledano : Test and genomic profile : what future in breast cancer trea...
Alain Toledano : Test and genomic profile : what future in breast cancer trea...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdfCritical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdf
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
CRC CHP final PDF
CRC CHP final PDFCRC CHP final PDF
CRC CHP final PDF
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
 
Cadher
CadherCadher
Cadher
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
 
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
Circulatingtumordna (Ctdna) in Prostate Cancer: Current Insights and New Pers...
 

More from Melanoma Research Foundation

Ocumel Ireland - 2019 CURE OM Symposium
Ocumel Ireland - 2019 CURE OM SymposiumOcumel Ireland - 2019 CURE OM Symposium
Ocumel Ireland - 2019 CURE OM Symposium
Melanoma Research Foundation
 
OcuMel UK - 2019 CURE OM Symposium
OcuMel UK - 2019 CURE OM SymposiumOcuMel UK - 2019 CURE OM Symposium
OcuMel UK - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Ocumel Canada - 2019 CURE OM Symposium
Ocumel Canada - 2019 CURE OM SymposiumOcumel Canada - 2019 CURE OM Symposium
Ocumel Canada - 2019 CURE OM Symposium
Melanoma Research Foundation
 
2019 CURE OM Symposium
2019 CURE OM Symposium2019 CURE OM Symposium
2019 CURE OM Symposium
Melanoma Research Foundation
 
About CURE OM - 2019 CURE OM Symposium
About CURE OM - 2019 CURE OM SymposiumAbout CURE OM - 2019 CURE OM Symposium
About CURE OM - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Metastatic Uveal Melanoma Treatment - 2019 CURE OM Symposium
Metastatic Uveal Melanoma Treatment - 2019 CURE OM SymposiumMetastatic Uveal Melanoma Treatment - 2019 CURE OM Symposium
Metastatic Uveal Melanoma Treatment - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Uveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM SymposiumUveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Melanoma Research Foundation
 
CURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM SymposiumCURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Targeted Therapy Clinical Trial Update - 2019 CURE OM Symposium
Targeted Therapy Clinical Trial Update - 2019 CURE OM SymposiumTargeted Therapy Clinical Trial Update - 2019 CURE OM Symposium
Targeted Therapy Clinical Trial Update - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Unique Populations - 2019 CURE OM Symposium
Unique Populations - 2019 CURE OM SymposiumUnique Populations - 2019 CURE OM Symposium
Unique Populations - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Auburn Uveal Melanoma Study - 2019 CURE OM Symposium
Auburn Uveal Melanoma Study - 2019 CURE OM SymposiumAuburn Uveal Melanoma Study - 2019 CURE OM Symposium
Auburn Uveal Melanoma Study - 2019 CURE OM Symposium
Melanoma Research Foundation
 
The Past, Present and Future of Uveal Melanoma - 2019 CURE OM Symposium
The Past, Present and Future of Uveal Melanoma - 2019 CURE OM SymposiumThe Past, Present and Future of Uveal Melanoma - 2019 CURE OM Symposium
The Past, Present and Future of Uveal Melanoma - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Clinical Trials Panel Discussion: 2019 CURE OM Symposium
Clinical Trials Panel Discussion: 2019 CURE OM SymposiumClinical Trials Panel Discussion: 2019 CURE OM Symposium
Clinical Trials Panel Discussion: 2019 CURE OM Symposium
Melanoma Research Foundation
 
Welcome - 2019 CURE OM Symposium
Welcome - 2019 CURE OM SymposiumWelcome - 2019 CURE OM Symposium
Welcome - 2019 CURE OM Symposium
Melanoma Research Foundation
 
Radiology Basics
Radiology BasicsRadiology Basics
Balancing Work, Life and Melanoma Treatment
Balancing Work, Life and Melanoma TreatmentBalancing Work, Life and Melanoma Treatment
Balancing Work, Life and Melanoma Treatment
Melanoma Research Foundation
 
A Potential Molecular Target for the Treatment of Uveal Melanoma
A Potential Molecular Target for the Treatment of Uveal MelanomaA Potential Molecular Target for the Treatment of Uveal Melanoma
A Potential Molecular Target for the Treatment of Uveal Melanoma
Melanoma Research Foundation
 
Liver Directed Therapies
Liver Directed TherapiesLiver Directed Therapies
Liver Directed Therapies
Melanoma Research Foundation
 
Understanding Scans 101
Understanding Scans 101Understanding Scans 101
Understanding Scans 101
Melanoma Research Foundation
 
Ocular Melanoma Cluster Update
Ocular Melanoma Cluster UpdateOcular Melanoma Cluster Update
Ocular Melanoma Cluster Update
Melanoma Research Foundation
 

More from Melanoma Research Foundation (20)

Ocumel Ireland - 2019 CURE OM Symposium
Ocumel Ireland - 2019 CURE OM SymposiumOcumel Ireland - 2019 CURE OM Symposium
Ocumel Ireland - 2019 CURE OM Symposium
 
OcuMel UK - 2019 CURE OM Symposium
OcuMel UK - 2019 CURE OM SymposiumOcuMel UK - 2019 CURE OM Symposium
OcuMel UK - 2019 CURE OM Symposium
 
Ocumel Canada - 2019 CURE OM Symposium
Ocumel Canada - 2019 CURE OM SymposiumOcumel Canada - 2019 CURE OM Symposium
Ocumel Canada - 2019 CURE OM Symposium
 
2019 CURE OM Symposium
2019 CURE OM Symposium2019 CURE OM Symposium
2019 CURE OM Symposium
 
About CURE OM - 2019 CURE OM Symposium
About CURE OM - 2019 CURE OM SymposiumAbout CURE OM - 2019 CURE OM Symposium
About CURE OM - 2019 CURE OM Symposium
 
Metastatic Uveal Melanoma Treatment - 2019 CURE OM Symposium
Metastatic Uveal Melanoma Treatment - 2019 CURE OM SymposiumMetastatic Uveal Melanoma Treatment - 2019 CURE OM Symposium
Metastatic Uveal Melanoma Treatment - 2019 CURE OM Symposium
 
Uveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM SymposiumUveal Melanoma Liver Metastases - 2019 CURE OM Symposium
Uveal Melanoma Liver Metastases - 2019 CURE OM Symposium
 
CURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM SymposiumCURE OM Patient Registry Update - 2019 CURE OM Symposium
CURE OM Patient Registry Update - 2019 CURE OM Symposium
 
Targeted Therapy Clinical Trial Update - 2019 CURE OM Symposium
Targeted Therapy Clinical Trial Update - 2019 CURE OM SymposiumTargeted Therapy Clinical Trial Update - 2019 CURE OM Symposium
Targeted Therapy Clinical Trial Update - 2019 CURE OM Symposium
 
Unique Populations - 2019 CURE OM Symposium
Unique Populations - 2019 CURE OM SymposiumUnique Populations - 2019 CURE OM Symposium
Unique Populations - 2019 CURE OM Symposium
 
Auburn Uveal Melanoma Study - 2019 CURE OM Symposium
Auburn Uveal Melanoma Study - 2019 CURE OM SymposiumAuburn Uveal Melanoma Study - 2019 CURE OM Symposium
Auburn Uveal Melanoma Study - 2019 CURE OM Symposium
 
The Past, Present and Future of Uveal Melanoma - 2019 CURE OM Symposium
The Past, Present and Future of Uveal Melanoma - 2019 CURE OM SymposiumThe Past, Present and Future of Uveal Melanoma - 2019 CURE OM Symposium
The Past, Present and Future of Uveal Melanoma - 2019 CURE OM Symposium
 
Clinical Trials Panel Discussion: 2019 CURE OM Symposium
Clinical Trials Panel Discussion: 2019 CURE OM SymposiumClinical Trials Panel Discussion: 2019 CURE OM Symposium
Clinical Trials Panel Discussion: 2019 CURE OM Symposium
 
Welcome - 2019 CURE OM Symposium
Welcome - 2019 CURE OM SymposiumWelcome - 2019 CURE OM Symposium
Welcome - 2019 CURE OM Symposium
 
Radiology Basics
Radiology BasicsRadiology Basics
Radiology Basics
 
Balancing Work, Life and Melanoma Treatment
Balancing Work, Life and Melanoma TreatmentBalancing Work, Life and Melanoma Treatment
Balancing Work, Life and Melanoma Treatment
 
A Potential Molecular Target for the Treatment of Uveal Melanoma
A Potential Molecular Target for the Treatment of Uveal MelanomaA Potential Molecular Target for the Treatment of Uveal Melanoma
A Potential Molecular Target for the Treatment of Uveal Melanoma
 
Liver Directed Therapies
Liver Directed TherapiesLiver Directed Therapies
Liver Directed Therapies
 
Understanding Scans 101
Understanding Scans 101Understanding Scans 101
Understanding Scans 101
 
Ocular Melanoma Cluster Update
Ocular Melanoma Cluster UpdateOcular Melanoma Cluster Update
Ocular Melanoma Cluster Update
 

Recently uploaded

Microbiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the MicroscopeMicrobiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the Microscope
ThaShee2
 
All about shoulder Joint ..
All about shoulder Joint .. All about shoulder Joint ..
All about shoulder Joint ..
Aswan University Hospital
 
Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx
Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptxCan Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx
Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx
FFragrant
 
RESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiyaRESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiya
Bhavyakelawadiya
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) CosmeticsStoryboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
MuskanShingari
 
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl MumbaiCall Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Mobile Problem
 
Call Girls Goa (india) +91-7426014248 Goa Call Girls
Call Girls Goa (india) +91-7426014248 Goa Call GirlsCall Girls Goa (india) +91-7426014248 Goa Call Girls
Call Girls Goa (india) +91-7426014248 Goa Call Girls
sagarvarma453
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Kunj Vihari
 
ENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community settingENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community setting
ShraddhaTamshettiwar
 
Allopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptxAllopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptx
Madhumita Dixit
 
2nd-generation Antihistaminic Part I.pptx
2nd-generation Antihistaminic Part I.pptx2nd-generation Antihistaminic Part I.pptx
2nd-generation Antihistaminic Part I.pptx
Madhumita Dixit
 
anatomy of submandibular region presentation
anatomy of submandibular region presentationanatomy of submandibular region presentation
anatomy of submandibular region presentation
MalaM67
 
Brain specific drug delivery.pptx -Mpharm
Brain specific drug delivery.pptx -MpharmBrain specific drug delivery.pptx -Mpharm
Brain specific drug delivery.pptx -Mpharm
MuskanShingari
 
Call Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls PuneCall Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls Pune
Mobile Problem
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Jim Jacob Roy
 
Pharmacology of Drugs for Congestive Heart Failure
Pharmacology of Drugs for Congestive Heart FailurePharmacology of Drugs for Congestive Heart Failure
Pharmacology of Drugs for Congestive Heart Failure
Dr. Nikhilkumar Sakle
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
TigistuMelak
 
Patellar Instability: Diagnosis Management
Patellar Instability: Diagnosis  ManagementPatellar Instability: Diagnosis  Management
Patellar Instability: Diagnosis Management
Dr Nitin Tyagi
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
shruti jagirdar
 

Recently uploaded (20)

Microbiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the MicroscopeMicrobiology & Parasitology Exercises Parts of the Microscope
Microbiology & Parasitology Exercises Parts of the Microscope
 
All about shoulder Joint ..
All about shoulder Joint .. All about shoulder Joint ..
All about shoulder Joint ..
 
Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx
Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptxCan Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx
Can Traditional Chinese Medicine Treat Blocked Fallopian Tubes.pptx
 
RESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiyaRESPIRATORY DISEASES by bhavya kelavadiya
RESPIRATORY DISEASES by bhavya kelavadiya
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) CosmeticsStoryboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
 
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl MumbaiCall Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
 
Call Girls Goa (india) +91-7426014248 Goa Call Girls
Call Girls Goa (india) +91-7426014248 Goa Call GirlsCall Girls Goa (india) +91-7426014248 Goa Call Girls
Call Girls Goa (india) +91-7426014248 Goa Call Girls
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
 
ENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community settingENVIRONMENTAL SANITATION in community setting
ENVIRONMENTAL SANITATION in community setting
 
Allopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptxAllopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptx
 
2nd-generation Antihistaminic Part I.pptx
2nd-generation Antihistaminic Part I.pptx2nd-generation Antihistaminic Part I.pptx
2nd-generation Antihistaminic Part I.pptx
 
anatomy of submandibular region presentation
anatomy of submandibular region presentationanatomy of submandibular region presentation
anatomy of submandibular region presentation
 
Brain specific drug delivery.pptx -Mpharm
Brain specific drug delivery.pptx -MpharmBrain specific drug delivery.pptx -Mpharm
Brain specific drug delivery.pptx -Mpharm
 
Call Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls PuneCall Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls Pune
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
 
Pharmacology of Drugs for Congestive Heart Failure
Pharmacology of Drugs for Congestive Heart FailurePharmacology of Drugs for Congestive Heart Failure
Pharmacology of Drugs for Congestive Heart Failure
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
 
Patellar Instability: Diagnosis Management
Patellar Instability: Diagnosis  ManagementPatellar Instability: Diagnosis  Management
Patellar Instability: Diagnosis Management
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
 

Unique Populations - 2019 CURE OM Symposium

  • 1. Discover. Educate. Care. Lead. Genomic Analysis of Unique Uveal Melanoma (UM) Cases
  • 2. Huntersville Project 22 reported cases of uveal melanoma in Huntersville, NC (15 females, 7 males) Consented 11 patients/family members for archival tissue collection Obtained 7 primary (6 enucleation, 1 FNA) and 2 metastatic (liver) tumor samples *Tissue missing or inadequate in other cases Whole genome sequencing (40X-80X) on 6 enucleation and 2 liver samples underway – anticipate results in May-June 2019
  • 3. DNA Structure National Human Genome Research Institute DNA Structure | BioNinja
  • 4. Whole Genome Sequencing (WGS) Figure out the cancer’s entire DNA sequence (all 6.4 billion letters)  Step 1: Separate tumor and adjacent normal tissue  Step 2: Extract DNA from tumor and matched normal tissue  Step 3: Whole genome sequencing (New York Genome Center) National Human Genome Research Institute corneaoptic nerve tumor
  • 5. What can we learn from WGS? Whole genome sequencing Compare to public genome databases e.g. The Cancer Genome Atlas Compare to genomic data from other unique UM populations e.g. Auburn, AL Identify mutational signatures that may point to carcinogen exposure or specific mutational process More thorough evaluation of key driver mutations such as BAP1
  • 6. Molecular landscape of uveal melanoma Field MG et al. Nature Communications 2018. Royer-Bertrand B et al. Am J Hum Genet 2016.
  • 7. UV mutational signature Relationship between UV exposure and UM risk is unclear: welding identified as significant risk factor, but all forms of sun exposure were non-significant Characterized by CT transitions at pyrimidine dimers, including CCTT https://courses.lumenlearning.com/microbiology/chapter/mutations/ https://cancer.sanger.ac.uk/cosmic/signatures UV light triggers formation of covalent bonds between adjacent cytosine (C) or thymine (T) bases leads to DNA kinking and faulty replication Pyrimidine dimer Pyrimidine dimer Error-prone polymerase misreads template C to T mutation at site of adjacent pyrimidines
  • 8. Tobacco mutational signature High prevalence of CA transversions on transcribed strand Polycyclic hydrocarbons and other carcinogens found in tobacco smoke interact with DNA to form bulky adducts on guanine (G) Principles of Cancer Biology, ©2006 Pearson en.wikipidia.org Activated benzo(a)pyrene
  • 9. 30 identified mutational signatures Signature 22. Aristolochic acid Signature 24. Aflatoxin B1 Signature 2. Activated APOBEC (possible viral etiology)

Editor's Notes

  1. Hi, I’m Jessica, one of the medical oncology fellows working with Dr. Carvajal at Columbia University. I just wanted to spend a few minutes discussing some the work we’ve done so far in analyzing the tumor samples from Huntersville, NC and to briefly review what we ultimately hope to learn.
  2. Of the 22 reported cases, we consented 11 patients/family members allowing us to obtain and use any leftover tumor tissue. We were able to get 7 primary tumor samples (one of which was a needle aspiration so there really wasn’t enough material to be used) and 2 liver samples. DNA was extracted from the 6 enucleation samples and 2 liver samples, and these were sent to the NYGC for whole genome sequencing. So what is whole genome sequencing, what does the whole process entail, and why is it taking so long?
  3. So just to start with the basics, nearly every cell in the human body including cancer cells contains a complete set of DNA, which provide the genetic instructions that influence everything from a person’s hair color to disease susceptibility to how a cancer cell develops and spreads. Cell there are different structures inside including the nucleus contains DNA in the form of chromosomes which you can think of as a very condensed and tightly wound form of DNA to allow it to fit inside the nucleus (humans have 23 pairs = 46 chromosomes)  if you untangle the chromosomes, DNA in its basic form resembles a long, twisty ladder formed by two strands of genetic material that connect to create what’s called a “double helix.” Each rung of the ladder joins together a pair of molecules called nucleotides: adenine (A), thymine (T), cytosine (C) and guanine (G). A always teams up with T, and C always pairs with G. Genes are made up of long stretches of DNA, and different genes or groups of genes are responsible for unique traits and cellular functions. Mutations or abnormalities in the DNA sequence can lead to diseases such as cancer, and these can either be inherited or develop randomly, sometimes in cases of exposure to specific mutagens or carcinogens.
  4. Whole genome sequencing is figuring out the order of the DNA nucleotides, or bases, in a genome—that is the order of the 6.4 billion As, Cs, Gs, and Ts that make up the cancer’s DNA. In order to perform WGS, you need both tumor and normal DNA since there has to be a reference sequence of letters against which we can compare the tumor DNA. This way, we can figure out the mutations that are unique to the cancer genome. The tumor samples arrive in the form of very thin sections of tissue that are mounted on glass slides. We ask the pathologist to look at the sample under the microscope to determine what’s tumor and what’s normal tissue. In the laboratory, we can then dissect away the tumor from the normal tissue and extract DNA from both tumor and normal tissue (this involves a number of different steps using chemicals to break open the cell membranes, gather the DNA, and strip away surrounding proteins to isolate just the DNA). The DNA samples are then sent to NYGC for analysis because they have a special protocol for sequencing DNA that’s taken from old, archival, formalin-fixed tissue. The whole genome can’t be sequenced at once since it’s billions of base pairs long so the DNA is first broken up into small overlapping pieces that are sequenced and then reassembled into the proper order using these overlaps, kind of like putting together a giant biological jigsaw puzzle. *** Compare that to the 17 million estimated to have had their DNA analyzed with direct-to-consumer tests sold by 23andMe and Ancestry. They use a technology called genotyping, which takes about a million snapshots of a person’s genome. That might sound like a lot, but it’s really less than 1 percent of the full picture. Genotyping targets short strings of DNA that scientists already know have a strong association with a given trait. So say, for example, scientists discover a new gene that increases your risk of developing brain cancer. If that gene is not one that 23andMe looks at (because how would it know to look if the gene hasn’t been discovered yet), then you’d have to get tested all over again to learn more about your brain cancer risk. Whole genome data on the other hand, once you have it, can be queried with computer algorithms whenever a new genetic discovery gets made.
  5. What are we hoping to learn from WGS? We can compare the genomic data to other unique UM populations such as Auburn, AL. We can also make comparisons to publicly available genomic data, such as The Cancer Genome Atlas, which contains sequencing information for 80 primary uveal melanomas, to see if there are any differences that may suggest a unique etiology. We can also look for different mutational signatures that may point to carcinogen exposure…
  6. Just to give you a sense of what we already know about the genetics of uveal melanoma, this is taken from a paper by Bill Harbour’s group in Miami. They analyzed 139 primary uveal melanoma samples using data from TCGA and other public databases. The horizontal axis represents different tumor samples, and the vertical axis lists the most common mutations. You’ve probably read or heard about GNAQ and GNA11 mutations which are found in virtually all uveal melanomas. This is a separate study where they compared the mutational profile of uveal melanoma to other types of cancers. The different colors represent different point mutations. For example, blue is C to A mutations where the C nucleotide is replaced by an A nucleotide. Orange is C to T, etc. You can see that the mutational profile of uveal melanoma at the bottom is quite different from skin melanoma and conjunctival melanoma, but maybe more similar to thyroid and kidney cancer. So it will be interesting to compare the sequencing data from the Huntersville and Auburn cases to these larger public databases to see what the similarities and differences are, not only with other melanomas, but also other types of cancer.
  7. Lastly, I just want to show you a few examples of common mutational signatures. We know that UV light is a risk factor for skin melanoma, but its relationship to uveal melanoma is less clear. In one study, welding was identified as a significant risk factor, but all other forms of sun exposure were non-significant. The UV mutational signature is characterized by ≥60% C→T transitions specifically at pyrimidine dimer sites (where there are two Cs or two Ts next to each other), including CC to TT changes. This arises because UV light triggers the formation of a bond/link between adjacent C or T bases. This causes the DNA to become kinked and misshapen so when it’s being replicated, errors are introduced where the C is replaced with a T.
  8. Tobacco is another common carcinogen that’s associated with a unique mutational signature characterized by a high prevalence of C to A changes. This occurs because polycyclic hydrocarbons and other carcinogens like benzo(a)pyrene interact with DNA to form bulky adducts on guanine (G). During the replication and repair process, the C:G base pair is replaced with an A:T base pair (C to A transversion since the C is on the transcribed strand). Cancer types:  Signature 4 has been found in head and neck cancer, liver cancer, lung adenocarcinoma, lung squamous carcinoma, small cell lung carcinoma, and oesophageal cancer. Proposed aetiology:  Signature 4 is associated with smoking and its profile is similar to the mutational pattern observed in experimental systems exposed to tobacco carcinogens (e.g., benzo[a]pyrene). Signature 4 is likely due to tobacco mutagens. Additional mutational features:  Signature 4 exhibits transcriptional strand bias for C>A mutations, compatible with the notion that damage to guanine is repaired by transcription-coupled nucleotide excision repair. Signature 4 is also associated with CC>AA dinucleotide substitutions. Comments:  Signature 29 is found in cancers associated with tobacco chewing and appears different from Signature 4.
  9. There are a total of 30 mutational signatures that have been identified associated with certain viral infections and other carcinogens like aflatoxin (produced by different fungi), but not all have a clear etiology. So it will be interesting to see if any of these signatures are found in the Huntersville cases. Cancer types:  Signature 2 has been found in 22 cancer types, but most commonly in cervical and bladder cancers. In most of these 22 cancer types, Signature 2 is present in at least 10% of samples. Proposed aetiology:  Signature 2 has been attributed to activity of the AID/APOBEC family of cytidine deaminases. On the basis of similarities in the sequence context of cytosine mutations caused by APOBEC enzymes in experimental systems, a role for APOBEC1, APOBEC3A and/or APOBEC3B in human cancer appears more likely than for other members of the family. Additional mutational features:  Transcriptional strand bias of mutations has been observed in exons, but is not present or is weaker in introns. Comments:  Signature 2 is usually found in the same samples as Signature 13. It has been proposed that activation of AID/APOBEC cytidine deaminases is due to viral infection, retrotransposon jumping or to tissue inflammation. Currently, there is limited evidence to support these hypotheses. A germline deletion polymorphism involving APOBEC3A and APOBEC3B is associated with the presence of large numbers of Signature 2 and 13 mutations and with predisposition to breast cancer. Mutations of similar patterns to Signatures 2 and 13 are commonly found in the phenomenon of local hypermutation present in some cancers, known as kataegis, potentially implicating AID/APOBEC enzymes in this process as well. Many of the other mutational signatures are associated with defective DNA repair pathways, and some don’t have a clear etiology.